---
title: "Tremfya (guselkumab) in plaque psoriasis: Clinical trials questions"
description: "Clinical trials questions on Tremfya (guselkumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Itch relief, Comparisons, Maintenance of response, Long-term results, Long-term data, and 2 further topics. Questions: How were the Tremfya plaque psoriasis trials PsO1 and PsO2 designed? How effective is Tremfya for plaque psoriasis at Week 16 (VOYAGE 1 and 2)? How fast does Tremfya improve plaque psoriasis? How many patients get completely clear skin on Tremfya at Week 24 (VOYAGE)? 12 further questions follow. 16 questions quoted from 11 sources."
canonical: "https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab) in plaque psoriasis: Clinical trials questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)

Questions that apply to every indication of Tremfya are on [Tremfya (guselkumab), all indications](https://www.evicenter.com/medical-information/tremfya).

## Clinical trials

<a id="tremfya-pivotal-trial-design"></a>

### How were the Tremfya plaque psoriasis trials PsO1 and PsO2 designed?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Four multicenter, randomized, double-blind trials (PsO1 [NCT02207231], PsO2 
> [NCT02207244], PsO3 [NCT02203032], and PsO4 [NCT02905331]) enrolled subjects 
> 18 years of age and older with moderate-to-severe plaque psoriasis who were 
> eligible for systemic therapy or phototherapy. Subjects had an Investigator’s Global 
> Assessment (IGA) score of ≥3 (“moderate”) on a 5-point scale of overall disease 
> severity, a Psoriasis Area and Severity Index (PASI) score ≥12, and a minimum 
> affected body surface area (BSA) of 10%. Subjects with guttate, erythrodermic, or 
> pustular psoriasis were excluded.”

Source: [TREMFYA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=7)

> “In trials PsO1 and PsO2, 1443 subjects were randomized to either TREMFYA (100 mg 
> at Weeks 0 and 4 and every 8 weeks thereafter) administered with a prefilled syringe, 
> placebo or U.S. licensed adalimumab (80 mg at Week 0 and 40 mg at Week 1, followed 
> by 40 mg every other week thereafter).”

Source: [TREMFYA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=7)

> “In both trials, subjects were predominantly men and White, with a mean age of 
> 44 years and a mean weight of 90 kg. At baseline, subjects had a median affected 
> BSA of approximately 21%, a median PASI score of 19, and 18% had a history of 
> psoriatic arthritis. Approximately 24% of subjects had an IGA score of 4 (“severe”). 
> In both trials, 23% had received prior biologic systemic therapy.”

Source: [TREMFYA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=7)

## Study results

<a id="tremfya-voyage-week-16"></a>

### How effective is Tremfya for plaque psoriasis at Week 16 (VOYAGE 1 and 2)?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “VOYAGE co-primary endpoints at Week 16 (NRI)<sup>1,2</sup>:
>
> VOYAGE 1—PASI 90: TREMFYA<sup>®</sup> 73% (241/329), placebo 3% (5/174) (P<0.001). IGA 0/1: TREMFYA<sup>®</sup> 85% (280/329), placebo 7% (12/174) (P<0.001). VOYAGE 2—PASI 90: TREMFYA<sup>®</sup> 70% (347/496), placebo 2% (6/248) (P<0.001). IGA 0/1: TREMFYA<sup>®</sup> 84% (417/496), placebo 8% (21/248) (P<0.001).”

Source: [TREMFYA: Skin Clearance Data: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/skin-clearance-data/#:~:text=VOYAGE%20co%2Dprimary%20endpoints%20at%20Week,%28417%2F496%29%2C%20placebo%208%25%20%2821%2F248%29%20%28P%3C0.001%29.)

<a id="tremfya-early-response"></a>

### How fast does Tremfya improve plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “VOYAGE 2: Mean PASI improvement from baseline<sup>1</sup>
>
> Week 4: 54% (n=496) with TREMFYA<sup>®</sup> vs 16% (n=248) with placebo
> Week 16: 89% (n=496) with TREMFYA<sup>®</sup> vs 20% (n=248) with placebo
>
> In the controlled period, mean PASI improvement was a prespecified other secondary analysis (TFR) that was not adjusted for multiplicity; P values were considered nominal.”

Source: [TREMFYA: Durability Data: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/durability-data/#mean-pasi-improvement:~:text=VOYAGE%202%3A%20Mean%20PASI%20improvement,P%20values%20were%20considered%20nominal.)

On the page, select: Mean PASI improvement

<a id="tremfya-complete-clearance"></a>

### How many patients get completely clear skin on Tremfya at Week 24 (VOYAGE)?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In VOYAGE 1 and VOYAGE 2 at Week 24 (major secondary endpoint, NRI)<sup>3-5§</sup>:
>
> 53% (61/115) of patients in VOYAGE 1 and 48% (76/160) of patients in VOYAGE 2 achieved IGA 0”

Source: [TREMFYA: VISIBLE: Moderate to Severe Plaque Psoriasis Skin Results, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/skin-tone/#complete-clearance:~:text=In%20VOYAGE%201%20and%20VOYAGE,VOYAGE%202%20achieved%20IGA%200)

On the page, select: Complete clearance data

> “<sup>§</sup>Results from North American sites only, which used a US-licensed active comparator. Active-comparator data not shown.”

Source: [TREMFYA: VISIBLE: Moderate to Severe Plaque Psoriasis Skin Results, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/skin-tone/#complete-clearance:~:text=from%20North%20American%20sites%20only%2C,comparator.%20Active%2Dcomparator%20data%20not%20shown.)

On the page, select: Complete clearance data

> “*IGA 0=proportion of patients who achieved an IGA score of cleared (0) using a 5-point scale where psoriatic lesions are graded by the investigator for induration, erythema, and scaling on a scale of 0 to 4: cleared, except for discoloration (0), minimal (1), mild (2), moderate (3), or severe (4).”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#:~:text=%2AIGA%200%3Dproportion%20of%20patients%20who,moderate%20%283%29%2C%20or%20severe%20%284%29.)

## Itch relief

<a id="tremfya-itch-symptoms"></a>

### Does Tremfya relieve psoriasis itch and other symptoms?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Greater improvements in symptoms of psoriasis (itch, pain, stinging, burning and 
> skin tightness) at Week 16 in TREMFYA compared to placebo were observed in 
> both trials based on the Psoriasis Symptoms and Signs Diary (PSSD). Greater 
> proportions of subjects on TREMFYA compared to U.S. licensed adalimumab 
> achieved a PSSD symptom score of 0 (symptom-free) at Week 24 in both trials.”

Source: [TREMFYA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=8)

## Comparisons

<a id="tremfya-vs-humira"></a>

### Tremfya vs Humira at Weeks 16 and 24: which cleared more skin in VOYAGE 2?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “VOYAGE 2: Major secondary endpoint at Week 16 (NRI)<sup>1,2</sup>*<sup>†</sup>
>
> 64% (102/160) of patients receiving TREMFYA<sup>®</sup> achieved PASI 90 vs 42% (34/81) of patients receiving Humira<sup>®</sup>
>
> VOYAGE 2: Major secondary endpoint at Week 24 (NRI)<sup>1,2</sup>*<sup>‡</sup>
>
> 71% (113/160) of patients receiving TREMFYA<sup>®</sup> achieved PASI 90 vs 51% (41/81) of patients receiving Humira<sup>®</sup>
>
> *Results from North American sites only, which used US-licensed Humira<sup>®</sup>.
>
> <sup>†</sup>P<0.001 vs Humira<sup>®</sup>.
>
> <sup>‡</sup>P=0.003 vs Humira<sup>®</sup>.”

Source: [TREMFYA: Skin Clearance Data: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/skin-clearance-data/#:~:text=VOYAGE%202%3A%20Major%20secondary%20endpoint,vs)

> “VOYAGE 2: Major secondary endpoint at Week 16 (NRI)<sup>1,2</sup>*<sup>‡</sup>
>
> 74% (119/160) of patients receiving TREMFYA<sup>®</sup> achieved IGA 0/1 vs 62% (50/81) of patients receiving Humira<sup>®</sup>
>
> VOYAGE 2: Major secondary endpoint at Week 24 (NRI)<sup>1,2</sup>*<sup>§</sup>
>
> 74% (119/160) of patients receiving TREMFYA<sup>®</sup> achieved IGA 0/1 vs 57% (46/81) of patients receiving Humira<sup>®</sup>
>
> Humira is a registered trademark of Abbvie Biotechnology Ltd. Corporation.
>
> Nonresponder imputation (NRI) methods were used for analysis.
>
> *Results from North American sites only, which used US-licensed Humira<sup>®</sup>.
>
> <sup>†</sup>P=0.001 vs Humira<sup>®</sup>.
>
> <sup>‡</sup>P=0.027 vs Humira<sup>®</sup>.
>
> <sup>§</sup>P=0.005 vs Humira<sup>®</sup>.”

Source: [TREMFYA: Skin Clearance Data: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/skin-clearance-data/#:~:text=74%25%20%28119%2F160%29%20of%20patients%20receiving,vs)

<a id="tremfya-vs-adalimumab-week-48"></a>

### Tremfya vs adalimumab at Week 48: how did they compare in VOYAGE 1?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “VOYAGE 1: Major secondary endpoint at Week 48<sup>1,2</sup>
>
> 73% (84/115) of patients receiving TREMFYA<sup>®</sup> achieved PASI 90 vs 46% (53/115) of patients receiving an active comparator (P<0.001)”

Source: [TREMFYA: Subpopulations: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/subpopulations/#body-weight:~:text=VOYAGE%201%3A%20Major%20secondary%20endpoint,receiving%20an%20active%20comparator%20%28P%3C0.001%29)

On the page, select: Body weight

> “Table 6 presents the results of an analysis of all the North America sites (i.e., U.S. 
> and Canada), demonstrating superiority of TREMFYA to U.S. licensed adalimumab.”

Source: [TREMFYA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=7)

> “Trials PsO1 and PsO2 (NRI<sup>a</sup>)
> Trial PsO1
> Trial PsO2
> Endpoint
> TREMFYA
> (N=115)<sup>b</sup>
> n (%)
> Adalimumab<sup>c</sup>
> (N=115)<sup>b</sup>
> n (%)
> TREMFYA
> (N=160)<sup>b</sup>
> n (%)
> Adalimumab<sup>c</sup>
> (N=81)<sup>b</sup>
> n (%)
> IGA response of 0/1 (“cleared” or “minimal”)
>    Week 16
> 97 (84)
> 70 (61)
> 119 (74)
> 50 (62)
>    Week 24
> 97 (84)
> 62 (54)
> 119 (74)
> 46 (57)
>    Week 48
> 91 (79)
> 62 (54)
> NA
> NA
> IGA response of 0 (“cleared”)
>    Week 24
> 61 (53)
> 27 (23)
> 76 (48)
> 23 (28)
>    Week 48
> 54 (47)
> 28 (24)
> NA
> NA
> PASI 75 response
>    Week 16
> 105 (91)
> 80 (70)
> 132 (83)
> 51 (63)
> PASI 90 response
>    Week 16
> 84 (73)
> 47 (41)
> 102 (64)
> 34 (42)
>    Week 24
> 92 (80)
> 51 (44)
> 113 (71)
> 41 (51)
>    Week 48
> 84 (73)
> 53 (46)
> NA
> NA
> <sup>a</sup> NRI = Non-Responder Imputation
> <sup>b</sup> Subjects from sites in the United States and Canada
> <sup>c</sup> U.S. licensed adalimumab”

Source: [TREMFYA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=7)

Note: The VOYAGE 1 Week 48 figures on the HCP page (84/115 and 53/115) match the Week 48 PASI 90 row for Trial PsO1 in label Table 6, which reports subjects from sites in the United States and Canada. In Table 6, the first two value columns are Trial PsO1 (TREMFYA, then adalimumab) and the last two are Trial PsO2; the label compares Week 48 results in Trial PsO1 only, so Trial PsO2 shows NA there.

<a id="tremfya-vs-cosentyx"></a>

### Tremfya vs Cosentyx: which was more effective at Week 48 (ECLIPSE)?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “ECLIPSE: Phase 3, double-blind trial (n=1048)”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#:~:text=ECLIPSE%3A%20Phase%203%2C%20double%2Dblind%20trial%20%28n%3D1048%29)

> “TREMFYA<sup>®</sup> demonstrated superiority vs Cosentyx<sup>®</sup> for PASI 90 response at Week 48<sup>1,2</sup>
> ECLIPSE: Primary endpoint at Week 48
>
> *P<0.001 vs Cosentyx<sup>®</sup>.”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#:~:text=demonstrated%20superiority%20vs,%2AP%3C0.001%20vs)

> “Secondary endpoint at Week 48
> IGA 0/1: TREMFYA<sup>®</sup> 85% (454/534), Cosentyx<sup>®</sup> 75% (385/514)”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#:~:text=8%25%20%2821%2F248%29%20%28P%3C0.001%29.-,Secondary%20endpoint%20at%20Week%2048,75%25%20%28385%2F514%29)

> “Results based on ECLIPSE: a single study of TREMFYA<sup>®</sup> vs Cosentyx<sup>®</sup>.”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#:~:text=Results%20based%20on%20ECLIPSE%3A%20a,vs)

> “*Superiority for the first major secondary endpoint, PASI 75 at both Week 12 and 48, was not achieved (TREMFYA<sup>®</sup> 84.6% vs Cosentyx<sup>®</sup> 80.2%; P=0.062); therefore, the remaining P values are nominal and not included in the presentation.”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#:~:text=%2ASuperiority%20for%20the%20first%20major,not%20included%20in%20the%20presentation.)

<a id="tremfya-vs-cosentyx-week-12"></a>

### Tremfya vs Cosentyx: how did they compare at Week 12 (ECLIPSE)?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “PASI 75 and IGA 0/1 at Week 12 (secondary endpoints at Week 12)
> PASI 75: TREMFYA<sup>®</sup> 89% (477/534), Cosentyx<sup>®</sup> 92% (471/514)
> IGA 0/1: TREMFYA<sup>®</sup> 86% (457/534), Cosentyx<sup>®</sup> 86% (444/514)
>
> Due to the results of the step-down approach to control for multiple testing, nominal P values for PASI 75 at Week 12 are not presented and efficacy comparisons cannot be made.
>
> IGA 0/1 at Week 12 was a prespecified exploratory endpoint that was not adjusted for multiplicity; P value was considered nominal.”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#:~:text=PASI%2075%20and%20IGA%200%2F1,P%20value%20was%20considered%20nominal.)

<a id="tremfya-stelara-inadequate-response"></a>

### Does Tremfya help after an inadequate response to Stelara (NAVIGATE)?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “NAVIGATE: Major secondary endpoint at Week 28 (12 weeks after randomization)”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#stelara:~:text=NAVIGATE%3A%20Major%20secondary%20endpoint%20at%20Week%2028%20%2812%20weeks%20after%20randomization%29)

On the page, select: vs STELARA®

> “*IGA ≥2 at Week 16 after initial treatment with US-licensed STELARA<sup>®</sup> (dosed 45 mg or 90 mg according to the patient's baseline weight at Week 0 or Week 4).”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#stelara:~:text=%2AIGA%20%E2%89%A52%20at%20Week%2016,Week%200%20or%20Week%204%29.)

On the page, select: vs STELARA®

> “<sup>†</sup>More than twice as many patients treated with TREMFYA<sup>®</sup> achieved IGA 0/1 (with a ≥2-grade improvement) at Week 28.”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#stelara:~:text=than%20twice%20as%20many%20patients,%E2%89%A52%2Dgrade%20improvement%29%20at%20Week%2028.)

On the page, select: vs STELARA®

> “<sup>‡</sup>P<0.001 vs STELARA<sup>®</sup>.”

Source: [TREMFYA: TREMFYA® vs Active Comparators In PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/tremfya-vs-active-comparator/#stelara:~:text=%E2%80%A1P%3C0.001%20vs%20STELARA%C2%AE.)

On the page, select: vs STELARA®

> “In subjects with an inadequate response (IGA ≥2 at Week 16 to U.S. licensed 
> ustekinumab), greater proportions of subjects on TREMFYA compared to U.S. 
> licensed ustekinumab achieved an IGA score of 0 or 1 with a ≥2 grade improvement 
> at Week 28 (31% vs. 14%, respectively; 12 weeks after randomization).”

Source: [TREMFYA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=8)

## Maintenance of response

<a id="tremfya-stopping-treatment"></a>

### What happens when Tremfya is stopped after a response (PsO2 withdrawal)?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “To evaluate maintenance and durability of response (trial PsO2), subjects 
> randomized to TREMFYA at Week 0 and who were PASI 90 responders at Week 28 
> were re-randomized to either continue treatment with TREMFYA every 8 weeks or 
> be withdrawn from therapy (i.e., receive placebo).
> At Week 48, 89% of subjects who continued on TREMFYA maintained PASI 90 
> compared to 37% of subjects who were re-randomized to placebo and withdrawn 
> from TREMFYA. For responders at Week 28 who were re-randomized to placebo and 
> withdrawn from TREMFYA, the median time to loss of PASI 90 was approximately 
> 15 weeks.”

Source: [TREMFYA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=8)

## Long-term results

<a id="tremfya-five-year-durability"></a>

### Does Tremfya keep working long term (5 years, VOYAGE 1)?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In a prespecified secondary analysis of efficacy after Week 48 applying treatment failure rules (TFR)<sup>1</sup>*<sup>†‡</sup>
>
> PASI 90: 80% (373/468) at Week 52; 82% (368/448) at Week 100; 83% (358/432) at Week 156; 82% (338/411) at Week 204; 84% (329/391) at Week 252
> IGA 0: 54% (251/468) at Week 52; 56% (249/448) at Week 100; 53% (229/430) at Week 156; 57% (234/410) at Week 204; 55% (214/391) at Week 252”

Source: [TREMFYA: Durability Data: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/durability-data/#:~:text=In%20a%20prespecified%20secondary%20analysis,55%25%20%28214%2F391%29%20at%20Week%20252)

> “Patients who lose response or are unable to tolerate treatment are likely to discontinue treatment, which may increase the response rate in an as-observed analysis.”

Source: [TREMFYA: Durability Data: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/durability-data/#:~:text=Patients%20who%20lose%20response%20or,rate%20in%20an%20as%2Dobserved%20analysis.)

> “<sup>†</sup>Available data at each visit were used; missing data were not included in the analysis.
>
> <sup>‡</sup>Data shown include patients randomized at Week 0 to the TREMFYA<sup>®</sup> arm and placebo-arm patients who crossed over to receive TREMFYA<sup>®</sup> at Weeks 16 and 20 and q8w thereafter.”

Source: [TREMFYA: Durability Data: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/durability-data/#:~:text=data%20at%20each%20visit%20were,and%2020%20and%20q8w%20thereafter.)

## Long-term data

<a id="tremfya-retention"></a>

### How many patients stay on Tremfya through 5 years?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “~8 out of 10 PsO patients continued therapy through 5 years”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/pso-retention-data/#:~:text=~8%20out%20of%2010%20PsO%20patients%20continued%20therapy%20through%205)

> “No conclusions regarding clinical efficacy or safety can be drawn.”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/pso-retention-data/#:~:text=No%20conclusions%20regarding%20clinical%20efficacy%20or%20safety%20can%20be%20drawn.)

> “*Year 5 represents Week 252.”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/pso-retention-data/#:~:text=%2AYear%205%20represents%20Week%20252.)

> “<sup>†</sup>Includes patients randomized to TREMFYA<sup>®</sup> and to placebo at baseline who crossed over to receive TREMFYA<sup>®</sup> at Week 16.”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/pso-retention-data/#:~:text=patients%20randomized%20to,at%20Week%2016.)

## Subgroup results

<a id="tremfya-scalp-psoriasis"></a>

### Does Tremfya work for scalp psoriasis?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “VOYAGE 1 and VOYAGE 2: Major secondary endpoint at Week 16 (NRI)<sup>5-7</sup>:
>
> VOYAGE 1—ss-IGA 0/1 and ≥2-grade improvement from baseline: TREMFYA<sup>®</sup> 83% (231/277), placebo 15% (21/145) (P<0.001)
>
> VOYAGE 2—ss-IGA 0/1 and ≥2-grade improvement from baseline: TREMFYA<sup>®</sup> 81% (329/408), placebo 11% (22/202) (P<0.001)
>
> An improvement was seen in psoriasis involving the scalp in subjects randomized to TREMFYA<sup>®</sup> compared to placebo at Week 16.”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=VOYAGE%201%20and%20VOYAGE%202%3A,to%20placebo%20at%20Week%2016.)

On the page, select: High-impact site data

<a id="tremfya-high-impact-sites"></a>

### How effective is Tremfya for scalp, face, skin-fold, and genital psoriasis (SPECTREM)?

Applies to: Adults with moderate plaque psoriasis, low body surface area involvement (2% to 15%), and high-impact site involvement (SPECTREM)

> “IN ADULT PATIENTS WITH MODERATE PLAQUE PSORIASIS”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=IN%20ADULT%20PATIENTS%20WITH%20MODERATE%20PLAQUE%20PSORIASIS)

On the page, select: High-impact site data

> “SPECTREM: Major secondary endpoints at Week 16 with a low-BSA* respective high-impact site
> score ≥3 at baseline (NRI)<sup>†</sup>”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=SPECTREM%3A%20Major%20secondary%20endpoints%20at,score%20%E2%89%A53%20at%20baseline)

On the page, select: High-impact site data

> “Scalp: 75%
>
> achieved skin clearance (ss-IGA 0/1) with TREMFYA<sup>®</sup> (114/152)
>
> vs 14% with placebo (11/76) (P<0.001)”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=Scalp%3A%2075%25,14%25%20with%20placebo%20%2811%2F76%29%20%28P%3C0.001%29)

On the page, select: High-impact site data

> “Intertriginous: 86%
>
> achieved skin clearance (i-IGA O/1) with TREMFYA<sup>®</sup> (96/111)
>
> vs 29% with placebo (15/52) (P<0.001)”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=Intertriginous%3A%2086%25,29%25%20with%20placebo%20%2815%2F52%29%20%28P%3C0.001%29)

On the page, select: High-impact site data

> “Face: 88%
>
> achieved skin clearance (f-IGA 0/1) with TREMFYA<sup>®</sup> (79/90)
>
> vs 29% with placebo (12/42) (P<0.001)”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=Face%3A%2088%25,29%25%20with%20placebo%20%2812%2F42%29%20%28P%3C0.001%29)

On the page, select: High-impact site data

> “Genital: 78%
>
> achieved skin clearance (sPGA-G) with TREMFYA<sup>®</sup> (64/82)
>
> vs 38% with placebo (15/40) (P<0.001)”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=Genital%3A%2078%25,38%25%20with%20placebo%20%2815%2F40%29%20%28P%3C0.001%29)

On the page, select: High-impact site data

> “*BSA criteria of 2%-15%.”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=%2ABSA%20criteria%20of%202%25%2D15%25.)

> “<sup>†</sup>P value is based on the chi-squared test, not adjusted for baseline stratification factor.”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=value%20is%20based%20on%20the,adjusted%20for%20baseline%20stratification%20factor.)

On the page, select: High-impact site data

> “BSA=body surface area; f-IGA=facial-IGA; IGA=Investigator’s Global Assessment; i-IGA=intertriginous-IGA; NRI=nonresponder imputation; sPGA-G=static Physician’s
> Global Assessment-genital; ss-IGA=scalp-specific IGA.”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#high-impact-site-data:~:text=BSA%3Dbody%20surface%20area%3B%20f%2DIGA%3Dfacial%2DIGA%3B%20IGA%3DInvestigator%E2%80%99s,Global%20Assessment%2Dgenital%3B%20ss%2DIGA%3Dscalp%2Dspecific%20IGA.)

On the page, select: High-impact site data

## Pediatric efficacy

<a id="tremfya-pediatric-efficacy"></a>

### How effective is Tremfya in children with plaque psoriasis at Week 16?

Applies to: Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy

> “In trial PsO5, 92 subjects were randomized to receive subcutaneous injection 
> of either TREMFYA (N=41) or placebo (N=25) at Weeks 0, 4, and 12 or an active 
> biological comparator (N=26). An additional 28 subjects enrolled in a TREMFYA 
> open-label arm. Subjects with a body weight of 70 kg or more received 100 mg of 
> TREMFYA. Subjects with a body weight less than 70 kg received doses according 
> to their weight.”

Source: [TREMFYA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=8)

> “Efficacy Results at Week 16 in Pediatric Subjects 6 Years of Age and 
> Older with Moderate-to-Severe Plaque Psoriasis in Trial PsO5 (NRI<sup>a</sup>)
> Endpoint
> Trial PsO5
> Placebo
> (N=25)
> n (%)
> TREMFYA
> (N=41)
> n (%)
> Treatment
> Difference
> (95% CI)
> IGA response of 0/1<sup>b,c</sup>
> 4 (16)
> 27 (66)
> 50 (26, 69)
> IGA response of 0 
> (cleared)
> 1 (4)
> 16 (39)
> 35 (11, 57)
> PASI 75 response
> 5 (20)
> 31 (76)
> 56 (32, 74)
> PASI 90 response<sup>b</sup>
> 4 (16)
> 23 (56)
> 40 (16, 61)
> PASI 100 response
> 0
> 14 (34)
> 34 (10, 56)
> <sup>a</sup>	NRI = Non-Responder Imputation
> <sup>b</sup>	Co-primary endpoint
> <sup>c</sup>	IGA response of 0 (”cleared”) or 1 (”minimal”)”

Source: [TREMFYA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=8)

> “The recommended dose for adults and pediatric patients 6 years of age and older who also weigh at least 40 kg is 100 mg.”

Source: [TREMFYA: Moderate To Severe Pediatric Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/pediatric/#:~:text=The%20recommended%20dose%20for%20adults,40%20kg%20is%20100%20mg.)

Note: Trial PsO5 used weight-based doses for subjects under 70 kg; the approved pediatric dose is 100 mg for patients 6 years of age and older who weigh at least 40 kg.

## Related pages
- [Medical information: Tremfya (guselkumab): Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/guidelines)
